ABSTRACT
OBJECTIVES: To assess the survival of patients who have received an operation for recurrent cervical and endometrial cancer and to determine prognostic variables for improved oncologic outcome. METHODS: A retrospective multicenter analysis of the medical records of 518 patients with cervical (N = 288) or endometrial cancer (N = 230) who underwent surgery for disease recurrence and who had completed at least 1 year of follow-up. RESULTS: The median survival reached 57 months for patients with cervical cancer and 113 months for patients with endometrial cancer after surgical treatment of recurrence (p = 0.036). Histological sub-type had a significant impact on overall survival, with the best outcome in endometrial endometrioid cancer (121 months), followed by cervical squamous cell carcinoma, cervical adenocarcinoma, or other types of endometrial cancer (81 vs 35 vs 35 months; p <0.001). The site of recurrence did not significantly influence survival in cervical or in endometrial cancer. Cancer stage at first diagnosis, tumor grade, lymph node status at recurrence, progression-free interval after first diagnosis, and free resection margins were associated with improved overall survival on univariate analysis. On multivariate analysis, the stage at first diagnosis and resection margins were significant independent predictive parameters of an improved oncologic outcome. CONCLUSION: Long-term survival can be achieved via secondary cytoreductive surgery in selected patients with recurrent cervical and endometrial cancer. An excellent outcome is possible even if the recurrence site is located in the lymph nodes. The possibility of achieving complete resection should be the main criterion for patient selection.
Subject(s)
Neoplasm Recurrence, Local/surgery , Uterine Neoplasms/surgery , Adult , Aged , Cancer Survivors , Cohort Studies , Cytoreduction Surgical Procedures/methods , Female , Humans , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Prognosis , Progression-Free Survival , Retrospective Studies , Salvage Therapy/methods , Survival Rate , Treatment Outcome , Uterine Cervical Neoplasms/mortality , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgery , Uterine Neoplasms/mortality , Uterine Neoplasms/pathologyABSTRACT
Somatic malignant transformation in mature cystic teratoma is a rare phenomenon of a malignancy of differentiated tissue structures of any stem line. The authors present a case of a 38-year-old female with mature cystic teratoma of both ovaries and with mucinous adenocarcinoma arising from endodermal germ line in the right ovary, showing immunohistochemical features of non-intestinal differentiation. At the time of diagnosis the tumour metastasized to the pelvic and retroperitoneal lymph nodes. The patient was treated with three lines of chemotherapy and died after 15 months with signs of massive progression into the retroperitoneal, mediastinal and cervical lymph nodes, retroperitoneum, duodenal wall and peritoneal cavity. Somatic malignant transformation in mature cystic teratoma is associated with poor prognosis. The most important prognostic factor is tumour stage at the time of diagnosis.